Discover why safety, durability, optimal hemodynamics and future coronary access are key when treating low- and intermediate-risk TAVI patients. Don't miss N. Van Mieghem reviewing the VANTAGE trial and Navitor™, highlighting very low one-year mortality and disabling stroke, no moderate or severe PVL and excellent valve haemodynamics.